Corbus Pharmaceuticals Holdings, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Corbus Pharmaceuticals Holdings, Inc. (CRBP) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $7.24 million as of 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-09
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $7.24M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $6.67M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $5.82M; Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed $5.82M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $8.66M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $7.24M 10-K · filed 2026-03-09 | |
| 2024-12-31 | $6.67M 10-K · filed 2026-03-09 | |
| 2023-12-31 | $5.82M 10-K · filed 2025-03-11 | $5.82M 10-K · filed 2024-03-12 |
| 2022-12-31 | $8.66M 10-K · filed 2024-03-12 | |
| 2021-12-31 | $9.10M 10-K · filed 2023-03-07 | |
| 2020-12-31 | $7.35M 10-K · filed 2022-03-08 | |
| 2019-12-31 | $5.37M 10-K · filed 2021-03-15 | |
| 2018-12-31 | $3.38M 10-K · filed 2020-03-16 | |
| 2017-12-31 | $1.72M 10-K · filed 2019-03-12 | |
| 2016-12-31 | $1.18M 10-K · filed 2018-03-12 | |
| 2015-12-31 | $453.91K 10-K · filed 2017-03-08 | |
| 2014-12-31 | $60.37K 10-K · filed 2016-03-28 | |
| 2013-12-31 | $2.41K 10-K · filed 2015-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |